- Report
- May 2025
- 136 Pages
Global
From €3585EUR$3,999USD£3,106GBP
- Report
- May 2025
- 200 Pages
Global
From €2232EUR$2,490USD£1,934GBP
- Report
- January 2026
- 189 Pages
Global
From €3178EUR$3,545USD£2,754GBP
€3531EUR$3,939USD£3,059GBP
- Report
- February 2026
- 250 Pages
Global
From €4025EUR$4,490USD£3,487GBP
- Report
- February 2026
- 250 Pages
Global
From €4025EUR$4,490USD£3,487GBP
- Report
- August 2025
- 200 Pages
United States
From €2232EUR$2,490USD£1,934GBP
- Report
- March 2026
- 376 Pages
Global
From €5244EUR$5,850USD£4,544GBP
- Report
- July 2025
- 350 Pages
Global
From €4436EUR$4,949USD£3,844GBP
- Report
- September 2025
- 593 Pages
Global
From €6270EUR$6,995USD£5,433GBP
- Report
- April 2025
- 171 Pages
Global
From €4392EUR$4,900USD£3,806GBP
- Report
- May 2025
- 146 Pages
Global
From €3585EUR$3,999USD£3,106GBP
- Report
- October 2025
- 150 Pages
Global
From €5334EUR$5,950USD£4,621GBP
- Report
- September 2025
- 138 Pages
Global
From €5334EUR$5,950USD£4,621GBP
- Report
- June 2025
- 320 Pages
Global
From €5334EUR$5,950USD£4,621GBP
- Report
- March 2026
- 278 Pages
Global
From €5244EUR$5,850USD£4,544GBP
- Report
- January 2026
- 187 Pages
Global
From €3178EUR$3,545USD£2,754GBP
€3531EUR$3,939USD£3,059GBP
- Report
- January 2026
- 186 Pages
Global
From €3178EUR$3,545USD£2,754GBP
€3531EUR$3,939USD£3,059GBP
- Report
- January 2026
- 181 Pages
Global
From €3178EUR$3,545USD£2,754GBP
€3531EUR$3,939USD£3,059GBP
- Report
- January 2026
- 191 Pages
Global
From €3178EUR$3,545USD£2,754GBP
€3531EUR$3,939USD£3,059GBP
- Report
- August 2025
- 193 Pages
Global
From €3178EUR$3,545USD£2,754GBP
€3531EUR$3,939USD£3,059GBP

The Tumor Profiling market within the Diagnostics industry is a rapidly growing sector. It involves the use of advanced technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to analyze the genetic makeup of tumors. This helps to identify the specific mutations that are driving the tumor's growth, allowing for more targeted treatments. Tumor profiling can also be used to monitor the effectiveness of treatments and to detect recurrence of the tumor.
The market is driven by the increasing prevalence of cancer, the growing demand for personalized medicine, and the development of new technologies. Additionally, the increasing availability of genomic data and the development of artificial intelligence (AI) and machine learning (ML) are expected to further drive the market.
Some of the major companies in the Tumor Profiling market include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and Roche. Show Less Read more